Sector News

Australia’s CSL buys Novartis flu vaccine unit for $275 mln

October 27, 2014
Life sciences
(Reuters) – Australia’s CSL Ltd , the world’s largest blood products company, said on Monday it had agreed to buy Novartis AG’s global influenza vaccine business for $275 million, part of the Swiss drugmaker’s drive to focus on its best assets.
 
The sale of the flu business will conclude Novartis’ overhaul of its units which it had flagged in April, aimed at strengthening its cancer business and exiting underperforming operations.
 
Novartis said in April GlaxoSmithKline was buying its vaccines business, excluding flu, for $5.25 billion plus potential milestone payments of up to $1.8 billion and royalties.
 
The sale of its flu business to CSL will trigger an exceptional pretax impairment charge of approximately $1.1 billion, as the selling price is below the book value of the assets, Novartis said in a statement on Monday.
 
The charge will be excluded from the Swiss drugmaker’s core results and a one-time operating income gain expected from the deal with GSK will compensate for the charge, it said.
 
Combining the Novartis unit with CSL subsidiary bioCSL would create the No.2 player in the $4 billion global influenza vaccine industry, CSL said in a statement to the Australian stock exchange.
 
CSL, which said it would fund the deal with surplus cash, estimated integration costs at $100 million, while synergy benefits were seen at $75 million a year by 2020.
 
The deal is expected to close in the second half of 2015, pending regulatory approval, Novartis said. (Reporting by Lincoln Feast in Sydney and Alice Baghdjian in Zurich; Editing by Robin Pomeroy and David Holmes)

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”